The value of CD73 expression in primary tumors as surrogate marker for the response to Cetuximab was tested in Cetuximab-treated PDX [23] and a cohort of advanced, metastatic HNSCC [5]. The gene discussed is NT5E; the disease is head and neck squamous cell carcinoma.